S-1: Revium Rx Files for IPO and Resale of Common Stock

Revium Rx, formerly OC Beverages, files an S-1 registration statement for an initial public offering of units and resale of common stock by selling stockholders.

Summary

• Revium Rx, a Nevada corporation, has filed a registration statement with the SEC for a self-underwritten initial public offering (IPO).
• The IPO consists of 1,562,500 units, each containing two shares of common stock and one warrant to purchase one share of common stock at an exercise price of $2.40.
• The units will be offered at a fixed price of $3.20 per unit until the common stock is quoted on the OTCQX or OTCQB marketplace or listed on a national securities exchange.
• The registration statement also covers the resale of up to 37,625,790 shares of common stock by selling stockholders.
• These shares include 31,253,525 shares of common stock, 4,925,000 shares issuable upon exercise of warrants at $0.80, and 1,447,265 shares issuable upon exercise of warrants at $2.40.
• The selling stockholders may sell their shares at a fixed price of $1.00 per share until the common stock is quoted on the OTCQX or OTCQB marketplace or listed on a national securities exchange, after which they may sell at prevailing market prices.
• Revium Rx will not receive any proceeds from the sale of common stock by the selling stockholders, except for funds received from the exercise of investor warrants.
• The company intends to use the net proceeds from the IPO for the development of product candidates and clinical trials (up to 80%) and to explore and develop additional new indications (up to 20%).
• The company's common stock is currently quoted on the OTC Pink marketplace under the symbol RVRC.
• The last reported sale price on February 13, 2025, was $0.50 per share.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The company is pursuing an IPO to fund its operations and has promising technology, but it also faces significant risks and challenges, including a history of losses and competition.

Positives

• The company has exclusive license rights to develop and market a novel technology related to Nano-Liposomal Particles (NLP)-based medicines.
• The company intends to use the net proceeds from the IPO primarily for the development of product candidates and clinical trials.
• The company has a well-defined production process for Nano-Mupirocin that has been scaled up to approximately a 5-liter batch.
• The company is developing a novel adjuvant to cancer therapies, a nanoparticles-based formulation of angiotensin receptor blockers (ARB) for intravenous administration.

Negatives

• The company has had no revenue and has incurred significant operating losses since inception and is expected to continue to incur significant operating losses for the foreseeable future.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• The company's stock price has been and may continue to be volatile, which could result in substantial losses for investors.
• An active trading market for the company's common stock may never develop or be sustained.
• The company's common stock is considered a penny stock, and any investment in its shares is considered to be a high-risk investment and is subject to restrictions on marketability.

Risks

• The company may not realize the anticipated benefits of the Share Exchange and succeeding to business of LipoVation.
• Failure to comply with LipoVations contractual obligations under the Yissum License Agreements may result in the loss of license rights.
• The company will need additional funding and it may not be available on acceptable terms.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company is subject to risks related to its dependency on key management members and other key personnel.
• Unsuccessful clinical trials or procedures relating to the company's product candidates under development could have a material adverse effect on its prospects.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• Conditions in Israel, including the ongoing war between Israel and Hamas and other conflicts in the region, may adversely affect the company's operations.
• The issuance of shares of Common Stock in the Primary Offering and upon exercise of the IPO Warrants could cause immediate and substantial dilution to existing stockholders.
• The company's stock price has been and may continue to be volatile, which could result in substantial losses for investors.

Future Outlook

The company expects to expand its clinical trials significantly, which will result in increasing losses, and may continue to incur substantial losses before it begins to generate revenues from the development and marketing of its technology.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on novel medicines and drug delivery systems. The company's success depends on its ability to develop and commercialize products that are safer, more effective, more convenient, or less expensive than existing therapies.

Comparison to Industry Standards

• The company's approach to drug delivery using nanoparticles is similar to that of companies like Matinas BioPharma and Encapsula NanoSciences.
• The company's development of cancer therapy adjuvants is competitive with companies like AstraZeneca, Roche, and Merck, which are also targeting the tumor microenvironment.
• The company's development of liposomal vaccines is competitive with companies like Pfizer-BioNTech and Moderna, which have successfully developed mRNA vaccines using lipid nanoparticles.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares in the IPO and upon exercise of warrants.
• Shareholders may benefit from the company's development of new products and potential commercial success.
• The company's success depends on its ability to attract and retain qualified personnel, which could impact employees.
• The company's development of new therapies could benefit patients with limited or no effective treatment options.

Next Steps

• The company intends to apply to upgrade its Common Stock to the OTCQB marketplace of OTC Market.
• The company plans to conduct a clinical development of Nano Mupirocin in collaboration with the National Institute of Health (NIH).
• The company plans to engage with major pharmaceutical companies regarding existing cancer therapy products, aiming to collaborate and integrate its adjuvant nano-ARB with approved treatments.
• Clinical trials for the ARB adjuvant therapy are planned to commence by end 2026.

Key Dates

Keywords

IPO, initial public offering, Revium Rx, common stock, warrants, resale, selling stockholders, LipoVation, clinical trials, pharmaceutical, biotechnology, Nano-Liposomal Particles, NLP, Mupirocin, Angiotensin Receptor Blocker, ARB, vaccine, Yissum, OTCQX, OTCQB, OTCPink